JPRN-jRCT2032220438已完成3 期
Confirmatory Study of KCB01 in PCI-eligible patients with coronary stenotic lesions that are difficult to expand with conventional POBA
akamura Masato0 个研究点目标入组 70 人开始时间: 2022年11月4日最近更新:
适应症
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
- 入组人数
- 70
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 20age old 至 ot applicable（—）
- 性别
- All
入选标准
- •(1) Japanese patients aged 20 years or older
- •(2) Patients with lesions that physicians consider difficult to dilate with conventional POBA and are eligible for PCI
- •(3) Patients with a confirmed diagnosis of class II or higher by CCS classification
- •(4) Patients with target lesion diameter between 2.0 mm and 4.0 mm (visual evaluation)
- •(5) Target lesion length is 38 mm or less (visual evaluation)
- •(6) Patients with target lesion diameter stenosis greater than 75% (visual evaluation)
- •(7) Patients with a 0.014-inch guidewire passing through the target lesion
- •(8) Patients in whom indentation of the target lesion could not be obtained by dilating the target lesion at the nominal pressure of a normal POBA (visual evaluation)
- •(9) Patients who have been fully informed about the investigational device and the purpose and details of the study, who voluntarily volunteer to participate in the study, and whose written consent to participate in the study has been obtained.
排除标准
- •(1) Patients with cardiogenic shock
- •(2) Patients after cardiopulmonary resuscitation
- •(3) Patients with a left ventricular ejection fraction (LVEF) of less than 40% within 30 days prior to the investigational procedure
- •(4) Patients with New York Heart Association (NYHA) Class III or IV heart failure
- •(5) Patients who have undergone PCI within 30 days prior to the study procedure or are scheduled to undergo PCI within 30 days after the study procedure
- •(6) Patients with evidence of acute myocardial infarction (STEMI or non-STEMI) within 30 days prior to the study procedure (CK value more than twice the institutional reference value or CK-MB elevation above the upper limit of the institutional reference value)
- •(7) Patients who have experienced a stroke or transient ischemic attack (TIA) within 6 months prior to the investigational procedure
- •(8) Patients who are not eligible for emergency CABG
- •(9) Patients with known contraindications or hypersensitivity reactions to aspirin, heparin, clopidogrel, ticlopidine, prasugrel, and ticagrelor
- •(10) Patients with a platelet count less than 100000
- •(11) Patients with a history or complication of peptic ulcer or gastrointestinal bleeding within 6 months prior to the investigational procedure
- •(12) Patients with diabetes mellitus and poor drug control
- •(13) Patients who are allergic to contrast media and cannot adequately respond to premedication
- •(14) Pregnant or lactating patients at the time of obtaining consent
- •(15) Patients with a medical condition with a life expectancy of less than 12 months
- •(16) Patients participating in other clinical trials at the time of consent
- •(17) Patients with unprotected left main coronary artery lesions (stenosis upper 50%) (visual evaluation)
- •(18) Patients whose target lesion is in a vessel that can only be reached through the saphenous vein or arterial bypass graft (including within an arterial bypass graft)
- •(19) Patients whose target lesion is located in or distal to a vessel with a bend of greater than 45 degrees in the target lesion (visual evaluation)
- •(20) Patients with excessive tortuosity (defined as the presence of two or more bends greater than 90 degrees or three or more bends greater than 75 degrees) in the target vessel (visual evaluation)
- •(21) Patients with thrombus or ulceration (by angiography or intravascular imaging) in the target vessel
- •(22) Patients with angiographic evidence of severe dissection (defined as type D or greater dissection in the NHLBI classification) in the target vessel after POBA dilation
- •(23) Patients whom the investigator or subinvestigator determines to be inappropriate to participate in the clinical trial
研究者
相似试验
已完成
2 期
Therapeutic exploratory study of KCB-1B for patients with tibial shaft fractureTibial shaft fractureJPRN-UMIN000000847Kaken Pharmaceutical Co.,Ltd.90
未知
2 期
Confirmatory clinical trial of KIB-PCI in healthy adult Japanese volunteersProphylaxis of new type of influenza infectionJPRN-jRCT2080221874DAIICHISANKYO Co.,Ltd.600
未知
2 期
Exploratory clinical trial of KIB-PCI in healthy Japanese childreProphylaxis of new type of influenza infectionJPRN-jRCT2080222144DAIICHISANKYO Co.,Ltd.30
进行中（未招募）
1 期
A Phase II study of BKM120 in patients with relapsed and refractory diffuse large B-cell lymphoma, mantle cell lymphoma and follicular lymphomaMedDRA version: 16.1Level: PTClassification code 10012822Term: Diffuse large B-cell lymphoma refractorySystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 16.1Level: PTClassification code 10026801Term: Mantle cell lymphoma refractorySystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2012-002208-41-DEovartis Pharma Services AG66
进行中（未招募）
1 期
A Phase II study of BKM120 in patients with relapsed and refractorydiffuse large B-cell lymphoma, mantle cell lymphoma and follicularlymphomaDiffuse large B-cell lymphoma, Mantle cell lymphoma and FollicularlymphomaMedDRA version: 14.1Level: PTClassification code 10012822Term: Diffuse large B-cell lymphoma refractorySystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 14.1Level: PTClassification code 10026801Term: Mantle cell lymphoma refractorySystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2012-002208-41-ESovartis Farmacéutica S.A.66